NCT01757262View on ClinicalTrials.gov

A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2013

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Coronary Heart Disease
Interventions
DRUG

90 mg Ticagrelor

Morning and Evening dose for 5 days

DRUG

75mg Clopidogrel

Morning dose for 5 days

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY